US6197786B1
(en)
*
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
GT199900147A
(es)
*
|
1998-09-17 |
1999-09-06 |
|
1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
|
US6147089A
(en)
*
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
SE0101161D0
(sv)
*
|
2001-03-30 |
2001-03-30 |
Astrazeneca Ab |
New compounds
|
US20030064967A1
(en)
*
|
2001-04-11 |
2003-04-03 |
Jayraz Luchoomun |
Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
|
MXPA03009936A
(es)
*
|
2001-04-30 |
2004-01-29 |
Pfizer Prod Inc |
Compuestos utiles como intermedios para derivados de 4-aminoquinolina.
|
CN1635911A
(zh)
*
|
2001-06-21 |
2005-07-06 |
辉瑞产品公司 |
胆固醇酯转运蛋白抑制剂的自乳化制剂
|
EA006777B1
(ru)
*
|
2001-06-22 |
2006-04-28 |
Пфайзер Продактс Инк. |
Фармацевтические композиции адсорбатов аморфного лекарственного средства
|
EP1269994A3
(en)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
PT1404300E
(pt)
|
2001-06-22 |
2009-11-09 |
Bend Res Inc |
Composições farmacêuticas de dispersões de fármacos e polímeros neutros
|
TW200303302A
(en)
*
|
2001-12-19 |
2003-09-01 |
Atherogenics Inc |
Chalcone derivatives and their use to treat diseases
|
WO2003053359A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
EP2305648A1
(en)
*
|
2001-12-21 |
2011-04-06 |
Novo Nordisk A/S |
Amide derivatives useful as glucokinase activators
|
BR0307344A
(pt)
*
|
2002-02-01 |
2004-12-14 |
Pfizer Prod Inc |
Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
JP4865989B2
(ja)
*
|
2002-02-01 |
2012-02-01 |
ベンド・リサーチ・インコーポレーテッド |
改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
|
PL371416A1
(en)
*
|
2002-02-01 |
2005-06-13 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
AU2003243921B2
(en)
*
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
US7504508B2
(en)
|
2002-10-04 |
2009-03-17 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US20090181966A1
(en)
*
|
2002-10-04 |
2009-07-16 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
WO2004032848A2
(en)
*
|
2002-10-04 |
2004-04-22 |
Millennium Pharmaceuticals, Inc. |
Pgd2 receptor antagonists for the treatment of inflammatory diseases
|
BR0315547A
(pt)
*
|
2002-10-21 |
2005-09-20 |
Warner Lambert Co |
Derivados de quinolina como antagonistas de crth2
|
AU2003289207A1
(en)
*
|
2002-12-06 |
2004-06-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-inflammatory agent
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
DE60331873D1
(de)
|
2002-12-20 |
2010-05-06 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
EP1435356A1
(en)
*
|
2003-01-06 |
2004-07-07 |
Warner-Lambert Company LLC |
Quinoline derivatives as CRTH2 antagonists
|
WO2004072042A2
(en)
*
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
BRPI0408442A
(pt)
*
|
2003-03-17 |
2006-04-04 |
Japan Tobacco Inc |
método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
|
ES2377121T3
(es)
*
|
2003-03-17 |
2012-03-22 |
Japan Tobacco Inc. |
Composiciones farmacéuticas de inhibidores de CETP
|
WO2004085401A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pfizer Products Inc. |
1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
|
US20040204450A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
TWI494102B
(zh)
*
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
WO2004106299A2
(en)
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
ATE540671T1
(de)
|
2003-08-04 |
2012-01-15 |
Bend Res Inc |
Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
KR20060080214A
(ko)
|
2003-09-26 |
2006-07-07 |
니뽄 다바코 산교 가부시키가이샤 |
잔여 리포프로테인 생산 저해 방법
|
MXPA06003499A
(es)
*
|
2003-09-30 |
2006-06-08 |
Pfizer Prod Inc |
Inhibidores de proteina de transferencia de esteres de colestrerilo y sus metabolitos.
|
ATE442358T1
(de)
*
|
2003-10-08 |
2009-09-15 |
Lilly Co Eli |
Verbindungen und verfahren zur behandlung von dyslipidemie
|
JP4839221B2
(ja)
*
|
2003-11-07 |
2011-12-21 |
ジェイ ジェイ ファーマ,インコーポレイテッド |
Hdlを高める併用療法用複合物
|
PL1723128T3
(pl)
*
|
2004-01-06 |
2013-04-30 |
Novo Nordisk As |
Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
|
CA2558766A1
(en)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
ATE402180T1
(de)
|
2004-03-26 |
2008-08-15 |
Lilly Co Eli |
Verbindungen zur behandlung von dyslipidemie
|
UA90269C2
(ru)
|
2004-04-02 |
2010-04-26 |
Мицубиси Танабе Фарма Корпорейшн |
Тетрагидрохинолиновые производные и способ их получения
|
TWI345568B
(en)
*
|
2004-04-02 |
2011-07-21 |
Mitsubishi Tanabe Pharma Corp |
Tetrahydronaphthyridine derivatives and a process for preparing the same
|
US20050282812A1
(en)
*
|
2004-06-18 |
2005-12-22 |
JONES Zachary |
Inhibitors of cholesteryl ester transfer protein
|
JP2008504266A
(ja)
*
|
2004-06-24 |
2008-02-14 |
イーライ リリー アンド カンパニー |
異脂肪血症を治療するための化合物及び方法
|
KR100859223B1
(ko)
*
|
2004-06-24 |
2008-09-18 |
일라이 릴리 앤드 캄파니 |
이상지혈증 치료를 위한 화합물 및 방법
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
DK1781265T3
(da)
|
2004-08-25 |
2010-08-02 |
Essentialis Inc |
Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US20070149567A1
(en)
*
|
2004-09-23 |
2007-06-28 |
Pfizer Inc |
Quinoline compounds
|
AP2007003979A0
(en)
*
|
2004-11-23 |
2007-06-30 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
|
US7700774B2
(en)
*
|
2004-12-20 |
2010-04-20 |
Dr. Reddy's Laboratories Ltd. |
Heterocyclic compounds and their pharmaceutical compositions
|
MX2007007919A
(es)
|
2004-12-31 |
2008-01-22 |
Reddy Us Therapeutics Inc |
Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
WO2006082518A1
(en)
|
2005-02-03 |
2006-08-10 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
AU2006216713A1
(en)
|
2005-02-24 |
2006-08-31 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
WO2006098394A1
(ja)
*
|
2005-03-14 |
2006-09-21 |
Japan Tobacco Inc. |
脂質吸収抑制方法および脂質吸収抑制剤
|
CN101212966B
(zh)
*
|
2005-07-01 |
2012-03-14 |
默沙东公司 |
合成cetp抑制剂的方法
|
ES2382815T3
(es)
*
|
2005-07-08 |
2012-06-13 |
Novo Nordisk A/S |
Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
|
CA2614518A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Novo-Nordisk A/S |
Dicycloalkyl urea glucokinase activators
|
CN101263131B
(zh)
|
2005-07-14 |
2013-04-24 |
特兰斯特克药品公司 |
脲葡糖激酶活化剂
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP4681526B2
(ja)
*
|
2005-09-29 |
2011-05-11 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4531027B2
(ja)
*
|
2005-09-29 |
2010-08-25 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101291662A
(zh)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
|
WO2007054896A1
(en)
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
PL1968601T3
(pl)
|
2006-01-05 |
2012-03-30 |
Essentialis Inc |
Sole związków otwierających kanały potasowe ATP i ich zastosowanie
|
UY30118A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compueto amina trisustituido
|
UY30117A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compuesto amina trisustituido
|
UY30244A1
(es)
|
2006-03-30 |
2007-11-30 |
Tanabe Seiyaku Co |
Un proceso para preparar derivados de tetrahidroquinolina
|
GB0615670D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Syngenta Participations Ag |
Chemical compounds
|
US7750019B2
(en)
|
2006-08-11 |
2010-07-06 |
Kowa Company, Ltd. |
Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
|
AR063275A1
(es)
*
|
2006-10-12 |
2009-01-14 |
Epix Delaware Inc |
Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
AU2007338625A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
|
JP2010515701A
(ja)
*
|
2007-01-09 |
2010-05-13 |
ノボ・ノルデイスク・エー/エス |
ウレアグルコキナーゼアクチベーター
|
US8318778B2
(en)
*
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
CN101220021B
(zh)
*
|
2007-01-12 |
2010-12-08 |
上海医药工业研究院 |
4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
|
US7790737B2
(en)
|
2007-03-13 |
2010-09-07 |
Kowa Company, Ltd. |
Substituted pyrimidine compounds and their utility as CETP inhibitors
|
NZ580777A
(en)
|
2007-04-13 |
2011-05-27 |
Kowa Co |
Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
|
JP2010532383A
(ja)
*
|
2007-07-02 |
2010-10-07 |
エッセンシャリス,インク. |
カリウムatpチャネル開口薬の塩およびその使用
|
ATE550333T1
(de)
|
2007-11-05 |
2012-04-15 |
Novartis Ag |
4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
|
WO2009071509A1
(en)
|
2007-12-03 |
2009-06-11 |
Novartis Ag |
1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
|
JP2011506466A
(ja)
|
2007-12-11 |
2011-03-03 |
株式会社サイトパスファインダー |
カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
|
BRPI1010600A2
(pt)
|
2009-05-15 |
2016-03-15 |
Novartis Ag |
aril piridina como inibidores de aldosterona sintase
|
EA201101621A1
(ru)
|
2009-05-15 |
2012-05-30 |
Новартис Аг |
Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
|
AU2010251967B9
(en)
|
2009-05-28 |
2014-04-03 |
Novartis Ag |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
UY32660A
(es)
|
2009-05-28 |
2010-12-31 |
Novartis Ag |
Derivados aminobutricos sustituidos como inhibidores de neprilisina
|
AR077208A1
(es)
|
2009-06-30 |
2011-08-10 |
Lilly Co Eli |
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
|
US8519134B2
(en)
|
2009-11-17 |
2013-08-27 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
ES2472446T3
(es)
|
2009-11-30 |
2014-07-01 |
Novartis Ag |
Derivados de imidazol como inhibidores de aldosterona sintasa
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
WO2012101142A1
(en)
|
2011-01-26 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for assessing a subject's risk of having a cardiovascular disease.
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
BR112013032557A2
(pt)
|
2011-06-17 |
2020-09-24 |
Merck Sharp & Dohe Corp. |
composto, formulação farmacêutica, uso de um composto, e, uso de um composto e um agente terap~eutico adicional
|
TWI537262B
(zh)
*
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
US9199967B2
(en)
|
2011-08-18 |
2015-12-01 |
Dr. Reddy's Laboratories Ltd. |
Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
|
CA2850022C
(en)
|
2011-09-27 |
2018-05-01 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
CA2900027A1
(en)
|
2013-02-14 |
2014-08-21 |
Novartis Ag |
Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
|
BR112015026513A2
(pt)
|
2013-04-17 |
2017-07-25 |
Pfizer |
derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
|
CN105705167A
(zh)
|
2013-07-25 |
2016-06-22 |
诺华股份有限公司 |
合成的apelin多肽的生物缀合物
|
EP3024845A1
(en)
|
2013-07-25 |
2016-06-01 |
Novartis AG |
Cyclic polypeptides for the treatment of heart failure
|
CN107072999A
(zh)
*
|
2014-08-28 |
2017-08-18 |
狄智玛制药私人有限公司 |
包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合
|
CA2959208C
(en)
|
2014-08-29 |
2023-09-19 |
Tes Pharma S.R.L. |
Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
BR112017014194A2
(pt)
|
2015-01-23 |
2018-01-09 |
Novartis Ag |
conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
KR20210020866A
(ko)
|
2018-06-12 |
2021-02-24 |
브이티브이 테라퓨틱스 엘엘씨 |
인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
|
EA202191892A1
(ru)
|
2019-01-18 |
2022-02-24 |
Астразенека Аб |
Ингибиторы pcsk9 и способы их применения
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|